Aug 22 2024 8 mins
Professor Matteo Giovanni Della Porta joins us to discuss the primary analysis of the phase 3 COMMANDS trial comparing luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndrome patients.